192 related articles for article (PubMed ID: 25760671)
1. Clinical drug interaction profile of idelalisib in healthy subjects.
Jin F; Robeson M; Zhou H; Moyer C; Wilbert S; Murray B; Ramanathan S
J Clin Pharmacol; 2015 Aug; 55(8):909-19. PubMed ID: 25760671
[TBL] [Abstract][Full Text] [Related]
2. The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment.
Jin F; Robeson M; Zhou H; Hisoire G; Ramanathan S
J Clin Pharmacol; 2015 Aug; 55(8):944-52. PubMed ID: 25821156
[TBL] [Abstract][Full Text] [Related]
3. Clinical Pharmacokinetic and Pharmacodynamic Profile of Idelalisib.
Ramanathan S; Jin F; Sharma S; Kearney BP
Clin Pharmacokinet; 2016 Jan; 55(1):33-45. PubMed ID: 26242379
[TBL] [Abstract][Full Text] [Related]
4. The pharmacokinetics and safety of idelalisib in subjects with severe renal impairment.
Jin F; Robeson M; Zhou H; Hisoire G; Ramanathan S
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1133-41. PubMed ID: 26526983
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetic modeling of idelalisib, a novel PI3Kδ inhibitor, in healthy subjects and patients with hematologic malignancies.
Jin F; Gao Y; Zhou H; Fang L; Li X; Ramanathan S
Cancer Chemother Pharmacol; 2016 Jan; 77(1):89-98. PubMed ID: 26645408
[TBL] [Abstract][Full Text] [Related]
6. The Drug-Drug Interaction Profile of Presatovir.
Xin Y; Weng W; Murray BP; Eisenberg EJ; Chien JW; Ling J; Silverman JA
J Clin Pharmacol; 2018 Jun; 58(6):771-780. PubMed ID: 29412463
[TBL] [Abstract][Full Text] [Related]
7. Clinical assessment of momelotinib drug-drug interactions via CYP3A metabolism and transporters.
Ho YL; Gorycki P; Ferron-Brady G; Martin P; Vlasakakis G
Clin Transl Sci; 2024 Apr; 17(4):e13799. PubMed ID: 38634429
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK.
Nguyen L; Holland J; Miles D; Engel C; Benrimoh N; O'Reilly T; Lacy S
J Clin Pharmacol; 2015 Sep; 55(9):1012-23. PubMed ID: 25854986
[TBL] [Abstract][Full Text] [Related]
9. Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design.
Reitman ML; Chu X; Cai X; Yabut J; Venkatasubramanian R; Zajic S; Stone JA; Ding Y; Witter R; Gibson C; Roupe K; Evers R; Wagner JA; Stoch A
Clin Pharmacol Ther; 2011 Feb; 89(2):234-42. PubMed ID: 21191377
[TBL] [Abstract][Full Text] [Related]
10. Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies.
Zurth C; Koskinen M; Fricke R; Prien O; Korjamo T; Graudenz K; Denner K; Bairlein M; von Bühler CJ; Wilkinson G; Gieschen H
Eur J Drug Metab Pharmacokinet; 2019 Dec; 44(6):747-759. PubMed ID: 31571146
[TBL] [Abstract][Full Text] [Related]
11. Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia.
Shah A; Mangaonkar A
Ann Pharmacother; 2015 Oct; 49(10):1162-70. PubMed ID: 26185276
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the Effects of Repeat-Dose Dabrafenib on the Single-Dose Pharmacokinetics of Rosuvastatin (OATP1B1/1B3 Substrate) and Midazolam (CYP3A4 Substrate).
Nebot N; Won CS; Moreno V; Muñoz-Couselo E; Lee DY; Gasal E; Bouillaud E
Clin Pharmacol Drug Dev; 2021 Sep; 10(9):1054-1063. PubMed ID: 33932130
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Pharmacokinetic Interactions Between Obeticholic Acid and Caffeine, Midazolam, Warfarin, Dextromethorphan, Omeprazole, Rosuvastatin, and Digoxin in Phase 1 Studies in Healthy Subjects.
Edwards JE; Eliot L; Parkinson A; Karan S; MacConell L
Adv Ther; 2017 Sep; 34(9):2120-2138. PubMed ID: 28808886
[TBL] [Abstract][Full Text] [Related]
14. Drug-Drug Interaction Study to Assess the Effect of Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of the Novel Cereblon Modulator Avadomide (CC-122) in Healthy Adult Subjects.
Ogasawara K; MacGorman K; Liu L; Chen J; Carayannopoulos LN; Zhou S; Palmisano M; Li Y
J Clin Pharmacol; 2019 Dec; 59(12):1620-1631. PubMed ID: 31172535
[TBL] [Abstract][Full Text] [Related]
15. Effect of Upadacitinib on the Pharmacokinetics of Rosuvastatin or Atorvastatin in Healthy Subjects.
Mohamed MF; Coppola S; Feng T; Camp HS; Kim E; Othman AA
Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1335-1344. PubMed ID: 34109764
[TBL] [Abstract][Full Text] [Related]
16. No Effect of Digoxin on Rosuvastatin Pharmacokinetics in Healthy Subjects: Utility of Oita Combination for Clinical Drug-Drug Interaction Study.
Otani N; Wakuda H; Imai H; Kuranari M; Ishii Y; Ito Y; Okubo A; Ogawa O; Takeda K; Ohyama T; Hasunuma T; Uemura N
Clin Transl Sci; 2019 Sep; 12(5):513-518. PubMed ID: 31095880
[TBL] [Abstract][Full Text] [Related]
17. PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.
Yahiaoui A; Meadows SA; Sorensen RA; Cui ZH; Keegan KS; Brockett R; Chen G; Quéva C; Li L; Tannheimer SL
PLoS One; 2017; 12(2):e0171221. PubMed ID: 28178345
[TBL] [Abstract][Full Text] [Related]
18. Management of adverse events associated with idelalisib treatment: expert panel opinion.
Coutré SE; Barrientos JC; Brown JR; de Vos S; Furman RR; Keating MJ; Li D; O'Brien SM; Pagel JM; Poleski MH; Sharman JP; Yao NS; Zelenetz AD
Leuk Lymphoma; 2015; 56(10):2779-86. PubMed ID: 25726955
[TBL] [Abstract][Full Text] [Related]
19. Idelalisib for the treatment of indolent non-Hodgkin's lymphoma.
Lopez JP; Jimeno A
Drugs Today (Barc); 2014 Feb; 50(2):113-20. PubMed ID: 24619588
[TBL] [Abstract][Full Text] [Related]
20. Phase 1b study to investigate the safety and tolerability of idelalisib in Japanese patients with relapsed/refractory follicular lymphoma and chronic lymphocytic leukemia.
Fukuhara N; Kinoshita T; Yamamoto K; Nagai H; Izutsu K; Yamamoto G; Bhargava P; Rajakumaraswamy N; Humeniuk R; Mathias A; Xing G; Fukui M; Tobinai K
Jpn J Clin Oncol; 2020 Dec; 50(12):1395-1402. PubMed ID: 32856068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
